Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia

Lignende værker

• Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
  af: Nilsson, Malin S., et al.
  Udgivet: (2019)
• NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
  af: Martner, Anna, et al.
  Udgivet: (2015)
• Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
  af: Sander, Frida Ewald, et al.
  Udgivet: (2017)
• Remission maintenance in acute myeloid leukemia: impact of functional histamine H(2) receptors expressed by leukemic cells
  af: Aurelius, Johan, et al.
  Udgivet: (2012)
• The HLA-B −21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia
  af: Hallner, Alexander, et al.
  Udgivet: (2019)